UPJOHN INC. DL-,0001 Logo
US45790W1080

UPJOHN INC. DL-,0001

Ins Portfolio

Kurse werden geladen...

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +13,53(+1.370,65%). Der Median liegt bei +12,91(+1.303,26%).

Kaufen
  6
Halten
  0
Verkaufen
  0

Scoring-Modelle

Dividenden-Strategie0 / 15
HGI-Strategie2 / 18
Levermann-Strategie-7 / 13
Powered byaktien.guide

News

  • Foto von Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

    Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

    - Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including an approximately 25% workforce reduction, expected to support operations into the first quarter of 2026 - - Enrollment complete in ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency; topline data expected in first quarter of 2026 - - Positive interim results from ENERGY 1 trial and Expanded Access Program evaluating INZ-701 in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease - BOSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc.  (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today reported financial results for the full year ended December 31, 2024, and provided recent business highlights. "2024 marked a transformative year for Inozyme as we achieved critical milestones in our ENPP1 Deficiency program that enabled us to complete enrollment in our pivotal ENERGY 3 trial and announce promising interim data in infants and young children with ENPP1 Deficiency in January 2025," said Douglas A.» Mehr auf globenewswire.com

  • Foto von Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference

    Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference

    BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, from 1:10-1:40pm ET.» Mehr auf globenewswire.com

  • Foto von Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025

    Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025

    BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer, will present recently announced data from the company's Expanded Access Program (EAP) evaluating INZ-701 in infants and children with ENPP1 Deficiency at the CHOP Cardiology Annual Meeting, held February 19-23, 2025, in Orlando, Florida.» Mehr auf globenewswire.com

Dividenden

Alle Kennzahlen
In 2022 hat UPJOHN INC. DL-,0001 +14,79 Dividende ausgeschüttet. Die letzte Dividende wurde im Juni 2022 gezahlt.

Unternehmenszahlen

Im letzten Quartal hatte UPJOHN INC. DL-,0001 einen Umsatz von 0,00 und ein Nettoeinkommen von 26,02 Mio
(EUR)Dez. 2024
YOY
Umsatz0,00100,00%
Bruttoeinkommen0,00100,00%
Nettoeinkommen26,02 Mio33,51%
EBITDA24,48 Mio51,15%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+59,23 Mio
Anzahl Aktien
64,24 Mio
52 Wochen-Hoch/Tief
+7,19 - +0,90
DividendenNein
Beta
1,31
KGV (PE Ratio)
0,62
KGWV (PEG Ratio)
+0,12
KBV (PB Ratio)
+1,09
KUV (PS Ratio)
0,00

Unternehmensprofil

Inozyme Pharma, Inc. ist ein biopharmazeutisches Unternehmen für seltene Krankheiten, das sich mit der Entwicklung von Therapeutika zur Behandlung von abnormaler Mineralisierung beschäftigt, die sich auf das Gefäßsystem, Weichgewebe und Skelett auswirkt. Der führende Produktkandidat des Unternehmens ist INZ-701, ein lösliches, rekombinantes Protein zur Behandlung der seltenen genetischen Krankheiten ENPP1- und ABCC6-Mangel sowie zur Behandlung von Calciphylaxie. Das Unternehmen hat eine Lizenzvereinbarung mit der Yale University für bestimmte therapeutische und prophylaktische Produkte abgeschlossen. Inozyme Pharma, Inc. wurde im Jahr 2015 gegründet und hat seinen Hauptsitz in Boston, Massachusetts.

Name
UPJOHN INC. DL-,0001
CEO
Dr. Douglas A. Treco Ph.D.
SitzBoston, ma
USA
Website
Industrie
Chemikalien
Börsengang
Mitarbeiter67

Ticker Symbole

BörseSymbol
NASDAQ
INZY
🍪

Parqet nutzt Cookies.Erfahre Mehr